Last reviewed · How we verify
NCT05304845
Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects
Phase 1 trial testing DWP14012 in Drug Drug Interaction in 24 participants. Completed in 22 May 2022.
22 May 2022
Quick facts
| Lead sponsor | Daewoong Pharmaceutical Co. LTD. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 24 |
| Start date | 21 March 2022 |
| Primary completion | 22 May 2022 |
| Estimated completion | 22 May 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
Conditions studied
- Drug Drug Interaction — all drugs for Drug Drug Interaction →
Sponsor
Daewoong Pharmaceutical Co. LTD. — full company profile →
Who can join
Adults 19 to 50, any sex, with Drug Drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, open-label study to evaluate the safety/tolerability and PK/PD drug-drug interactions between DWP14012 and aspirin when administered in combination.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects.
Oh J, Yang E, Jang IJ, Lee H, et al · · 2023 · cited 7× · PMID 36839870 · DOI 10.3390/pharmaceutics15020549
Verify or expand the search:
- PubMed search for NCT05304845
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DWP14012
Trials testing the same drug.
- NCT05812404 — Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects · Phase 1 · unknown
- NCT05574374 — Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects · Phase 1 · completed
- NCT05813561 — The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis · Phase 3 · completed
- NCT04888819 — Treatment Effect According to Timing of Administration of DWP14012 40 mg · NA · unknown
- NCT04613895 — Treatment Effect According to Timing of Administration of DWP14012 40 mg · NA · unknown
Other Daewoong Pharmaceutical Co. LTD. trials
Trials by the same sponsor.
- NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
- NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
- NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
- NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
- NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05304845 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
- Last refreshed: 5 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05304845.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing